NCT03557255View on ClinicalTrials.gov

Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

February 1, 2018

Study Completion Date

April 23, 2018

Conditions
Heart Failure
Interventions
DRUG

Levosimendan

Preoperative 24 hours infusion of levosimendan for chronic heart failure patients prior to major abdominal cancer surgeries.

DRUG

Saline

Preoperative 24 hours infusion of normal saline for chronic heart failure patients prior to major abdominal cancer surgeries.

Trial Locations (1)

11796

Department of Anesthesia and Pain medicine.National Cancer Institute, Cairo

All Listed Sponsors
lead

National Cancer Institute, Egypt

OTHER

NCT03557255 - Levosimendan for Cardiac Patients Undergoing Major Abdominal Cancer Surgeries | Biotech Hunter | Biotech Hunter